Scott A Waldman

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 17

Top Topics

Oxide Nanoparticles

Listeria Monocytogenes

Top Venues

NPJ Parkinson's disease

Biomarkers in medicine

Personalized medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Lara Cheslow, Adam E Snook, Scott A Waldman
Biomarkers for Managing Neurodegenerative Diseases. Biomolecules 14 (4) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
Lara Cheslow, Matthew Byrne, Jessica S Kopenhaver, Lorraine Iacovitti, Richard Jay Smeyne, Adam E Snook, Scott A Waldman
GUCY2C signaling limits dopaminergic neuron vulnerability to toxic insults. NPJ Parkinson's disease 10 (1) (2024)
John C Flickinger, Ross E Staudt, Jagmohan Singh, Robert D Carlson, Joshua R Barton, Trevor R Baybutt, Jeffrey A Rappaport, Alicja Zalewski, Amanda Pattison, Scott A Waldman, Adam E Snook
Chimeric adenoviral (Ad5.F35) and listeria vector prime-boost immunization is safe and effective for cancer immunotherapy. NPJ vaccines 7 (1) (2022)
Adi Caspi, Ariana A Entezari, Madison Crutcher, Adam E Snook, Scott A Waldman
Guanylyl cyclase C as a diagnostic and therapeutic target in colorectal cancer. Personalized medicine 19 (5) (2022)
Lara Cheslow, Adam E Snook, Scott A Waldman
Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers. Biomarkers in medicine 15 (8) (2021)
John C Flickinger, Jeffrey A Rappaport, Joshua R Barton, Trevor R Baybutt, Amanda M Pattison, Adam E Snook, Scott A Waldman
Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. Biomarkers in medicine 15 (3) (2021)
Ariana A Entezari, Adam E Snook, Scott A Waldman
Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert opinion on therapeutic targets 25 (5) (2021)
Alicja Zalewski, Adam E Snook, Scott A Waldman
Stem cells as therapeutic targets in colorectal cancer. Personalized medicine 18 (2) (2021)
David S Weinberg, Nathan R Foster, Gary Della'Zanna, Ryan P McMurray, Walter K Kraft, Angela Pallotto, David M Kastenberg, Leo C Katz, Christopher H Henry, Stephanie M Moleski, Paul J Limburg, Scott A Waldman
Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. Cancer biology & therapy (2021)
Scott A Waldman, Michael Camilleri
Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. Gut 67 (8) (2018)